vaayaa Inclusive Education
Healthcare 1 min read

FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List

May 01, 2026

FDA is proposing to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list, finding no clinical need for outsourcing facilities to compound these drugs from bulk substances.

Read full article on FDA Press Releases →

Source: FDA Press Releases — US Government, Public Domain

More in Healthcare

Can Ozempic prevent cancer? A doctor explains why the headlines are easy to misread The Conversation Health · 2 min Autistic children drown at alarming rates - swim lessons and water safety strategies can save their lives The Conversation Health · 2 min FDA Selects Seven Participants for PreCheck Pilot Program to Advance U.S. Drug Manufacturing FDA Press Releases · 1 min FDA Approves First Oral PCSK9 Inhibitor to Lower LDL Cholesterol in Adults with High Cholesterol FDA Press Releases · 1 min